Dinaciclib

Synonyms: SCH727965, PS-095760

Dinaciclib is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Dinaciclib induces apoptosis through the activation of caspases 8 and 9. Phase 3.

Dinaciclib Chemical Structure

Dinaciclib Chemical Structure

CAS No. 779353-01-4

Purity & Quality Control

Products often used together with Dinaciclib

MK-2206 2HCl


Dinaciclib and MK-2206 2HCl combination use dramatically blocks tumor growth and markedly reduces the number of metastatic lesions in the orthotopic Panc265/Panc253 models.


Hu C, et al. Mol Cancer Ther. 2015 Jul;14(7):1532-9.

SCH772984


Dinaciclib and SCH772984 combination use results in a more significant reduction in tumor growth than either treatment alone in mice.


Hayes TK, et al. Cancer Cell. 2016 Jan 11;29(1):75-89.

Rapamycin


Rapamycin administration to mice treated with LPS greatly improves gut inflammation and oxidative stress, while 3-methyladenine had the opposite effect.

Zhou M, et al. EBioMedicine. 2018 Sep;35:345-360.

Dinaciclib Related Products

Signaling Pathway

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CA46 Apoptosis Assay 100 nM 24 h induces cell cycle arrest 25289887
Kasumi-1 Apoptosis Assay 100 nM 24 h induces cell cycle arrest 25289887
U937 Function Assay 2/5/10 nM 3 h blocks induction of XBP-1s and downstream targets 24362465
8226 Function Assay 2/5/10 nM 4 h blocks induction of XBP-1s and downstream targets 24362465
H929 Function Assay 2/5/10 nM 4 h blocks induction of XBP-1s and downstream targets 24362465
K562 Function Assay 1.5/3/8 nM 6 h blocks induction of XBP-1s and downstream targets 24362465
BaF3/Bcr-abl Function Assay 1.5/3/8 nM 6 h blocks induction of XBP-1s and downstream targets 24362465
U937  Function Assay 2/10 nM 3 h blocks induction of XBP-1s and downstream targets 24362465
1205Lu Growth Inhibition Assay 10/30 nM 72 h inhibits cell growth and survival 23527225
WM1366 Growth Inhibition Assay 10/30 nM 72 h inhibits cell growth and survival 23527225
RD Growth Inhibition Assay IC50=8.2 nM 22315240
Rh41 Growth Inhibition Assay IC50=10.5 nM 22315240
Rh18 Growth Inhibition Assay IC50=10.5 nM 22315240
Rh30 Growth Inhibition Assay IC50=9 nM 22315240
BT-12 Growth Inhibition Assay IC50=8.5 nM 22315240
CHLA-266 Growth Inhibition Assay IC50=7.3 nM 22315240
TC-71 Growth Inhibition Assay IC50=3.9 nM 22315240
CHLA-9 Growth Inhibition Assay IC50=8 nM 22315240
CHLA-10 Growth Inhibition Assay IC50=6.3 nM 22315240
CHLA-258 Growth Inhibition Assay IC50=9.9 nM 22315240
GBM2 Growth Inhibition Assay IC50=6.5 nM 22315240
NB-1643 Growth Inhibition Assay IC50=3.3 nM 22315240
NB-EBc1 Growth Inhibition Assay IC50=7 nM 22315240
CHLA-90 Growth Inhibition Assay IC50=7.5 nM 22315240
CHLA-136 Growth Inhibition Assay IC50=9.8 nM 22315240
NALM-6 Growth Inhibition Assay IC50=4.6 nM 22315240
COG-LL-317 Growth Inhibition Assay IC50=6.5 nM 22315240
RS4;11 Growth Inhibition Assay IC50=5.1 nM 22315240
MOLT-4 Growth Inhibition Assay IC50=9.3 nM 22315240
CCRF-CEM Growth Inhibition Assay IC50=5.6 nM 22315240
Kasumi-1 Growth Inhibition Assay IC50=4.5 nM 22315240
Karpas-299 Growth Inhibition Assay IC50=3.9 nM 22315240
Ramos-RA1 Growth Inhibition Assay IC50=7.9 nM 22315240
MIAPaCa-2 Growth Inhibition Assay 72 h GI50=10 nM 21768779
Pa20C  Growth Inhibition Assay 72 h GI50=20 nM 21768779
ML-1 Apoptosis Assay 1-1000 nM 4 h induces apoptosis slightly 21768777
Cytotoxicity assay MDA-MB-436 72 hrs IC50 = 0.005 μM 23600925
Cytotoxicity assay NCI-H929 72 hrs IC50 = 0.005 μM 23600925
Cytotoxicity assay MDA-MB-231 72 hrs IC50 = 0.005 μM 23600925
Cytotoxicity assay SK-ES-1 72 hrs IC50 = 0.005 μM 23600925
Cytotoxicity assay A673 72 hrs IC50 = 0.005 μM 23600925
Cytotoxicity assay SK-BR-3 72 hrs IC50 = 0.005 μM 23600925
Cytotoxicity assay MNNG-HOS 72 hrs IC50 = 0.0055 μM 23600925
Cytotoxicity assay SK-UT-1 72 hrs IC50 = 0.006 μM 23600925
Cytotoxicity assay U266 72 hrs IC50 = 0.006 μM 23600925
Cytotoxicity assay RPMI18226 72 hrs IC50 = 0.009 μM 23600925
Cytotoxicity assay SW872 72 hrs IC50 = 0.0095 μM 23600925
Cytotoxicity assay T47D 72 hrs IC50 = 0.01 μM 23600925
Apoptosis assay A673 24 hrs EC50 = 0.011 μM 23600925
Cytotoxicity assay MCF7 72 hrs IC50 = 0.02 μM 23600925
Function assay Sf9 IC50 = 0.072 μM 26741853
Function assay sf9 IC50 = 0.002 μM 26851505
Function assay Sf9 1 hr IC50 = 0.001 μM 27171036
Function assay Sf9 1 hr IC50 = 0.001 μM 27171036
Function assay Sf9 1 hr IC50 = 0.001 μM 27171036
Function assay Sf9 1 hr IC50 = 0.001 μM 27171036
Function assay Sf9 1 hr IC50 = 0.003 μM 27171036
Function assay Sf9 1 hr IC50 = 0.003 μM 27171036
Function assay Sf9 1 hr IC50 = 0.004 μM 27171036
Function assay Sf9 1 hr IC50 = 0.004 μM 27171036
Function assay Sf9 10 uM IC50 = 0.004 μM 29329658
Function assay Sf9 1 hr IC50 = 0.001 μM 29853338
Function assay Sf9 1 hr IC50 = 0.001 μM 29853338
Function assay Sf9 1 hr IC50 = 0.003 μM 29853338
Function assay Sf9 1 hr IC50 = 0.004 μM 29853338
Antiproliferative assay MOLM13 72 hrs GI50 = 0.0033 μM 30253346
Antiproliferative assay MEC1 72 hrs GI50 = 0.0036 μM 30253346
Antiproliferative assay MOLM14 72 hrs GI50 = 0.0045 μM 30253346
Antiproliferative assay COLO205 72 hrs GI50 = 0.0068 μM 30253346
Antiproliferative assay HL60 72 hrs GI50 = 0.008 μM 30253346
Antiproliferative assay Ramos 72 hrs GI50 = 0.0086 μM 30253346
Antiproliferative assay GISTT1 72 hrs GI50 = 0.0088 μM 30253346
Antiproliferative assay U937 72 hrs GI50 = 0.01 μM 30253346
Antiproliferative assay A431 72 hrs GI50 = 0.011 μM 30253346
Antiproliferative assay SKM1 72 hrs GI50 = 0.011 μM 30253346
Antiproliferative assay MEC2 72 hrs GI50 = 0.011 μM 30253346
Antiproliferative assay A375 72 hrs GI50 = 0.011 μM 30253346
Antiproliferative assay OCI-AML3 72 hrs GI50 = 0.013 μM 30253346
Antiproliferative assay BE(2)-M17 72 hrs GI50 = 0.021 μM 30253346
Antiproliferative assay CHO 72 hrs GI50 = 0.16 μM 30253346
Function assay NCI-H929 0.005 uM 24 hrs Inhibition of CDK2-mediated Rb phosphorylation at Ser 807/811 in human NCI-H929 cells at 0.005 uM after 24 hrs by immunoblotting analysis 23600925
Function assay A673 0.05 uM 24 hrs Inhibition of CDK2-mediated Rb phosphorylation at Ser 807/811 in human A673 cells at 0.05 uM after 24 hrs by immunoblotting analysis 23600925
Apoptosis assay MEC1 0.01 uM 24 hrs Induction of apoptosis in human MEC1 cells assessed as decrease in MCL-1 level at 0.01 uM after 24 hrs by immunoblotting analysis 30253346
Apoptosis assay HL60 0.01 uM 24 hrs Induction of apoptosis in human HL60 cells assessed as decrease in MCL-1 level at 0.01 uM after 24 hrs by immunoblotting analysis 30253346
Apoptosis assay MV4-11 0.01 uM 24 hrs Induction of apoptosis in human MV4-11 cells assessed as decrease in c-MYC level at 0.01 uM after 24 hrs by immunoblotting analysis 30253346
Apoptosis assay MEC1 0.01 uM 24 hrs Induction of apoptosis in human MEC1 cells assessed as decrease in c-MYC level at 0.01 uM after 24 hrs by immunoblotting analysis 30253346
Apoptosis assay MV4-11 0.01 uM 24 hrs Induction of apoptosis in human MV4-11 cells assessed as decrease in MCL-1 level at 0.01 uM after 24 hrs by immunoblotting analysis 30253346
Apoptosis assay HL60 0.01 uM 24 hrs Induction of apoptosis in human HL60 cells assessed as decrease in c-MYC level at 0.01 uM after 24 hrs by immunoblotting analysis 30253346
Cytotoxicity assay U2OS 96 hrs IC50 = 0.006 μM ChEMBL
Function assay U2OS 1 hr IC50 = 0.007 μM ChEMBL
Click to View More Cell Line Experimental Data

Biological Activity

Description Dinaciclib is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Dinaciclib induces apoptosis through the activation of caspases 8 and 9. Phase 3.
Targets
CDK2 [1]
(Cell-free assay)
CDK5 [1]
(Cell-free assay)
CDK1 [1]
(Cell-free assay)
CDK9 [1]
(Cell-free assay)
1 nM 1 nM 3 nM 4 nM
In vitro
In vitro

Dinaciclib is also a potent DNA replication inhibitor that blocks thymidine (dThd) DNA incorporation in A2780 cells with IC50 of 4 nM. Dinaciclib strongly suppresses phosphorylation of Rb on Ser 807/811 at concentrations >6.25 nM, which is in agreement with the observation that 4 nM concentrations are required for 50% inhibition of dThd DNA incorporation in the same cell model. Significantly, complete suppression of Rb phosphorylation is correlated with the onset of apoptosis, as indicated by the appearance of the p85 PARP cleavage product in cells exposed to >6.25 nM Dinaciclib. Dinaciclib is active against a broad spectrum of human tumor cell lines. [1] Addition of Dinaciclib during exposure also suppresses accumulation of γ-H2AX, in a dose-dependent manner. [2] Dinaciclib inhibits melanoma cell proliferation, and drives melanoma cells into massive apoptosis. [3] Dinaciclib induces the apoptosis of several osteosarcoma cell lines including those resistant to doxorubicin. Dinaciclib attenuates the phosphorylation of RNAP II at serine 2 and the phosphorylation of the CDK inhibitor p27Kip1 at threonine 187. Reductions in phosphorylation activity occurrs at 12 - 40 nM Dinaciclib (4 to 16 hours post-Dinaciclib addition). Dinaciclib also reduces the phosphorylation of Rb at serine 807/811. Dinaciclib induces the apoptosis of mock- and p53-depleted U2OS cells to a similar extent. [4]

Kinase Assay Cyclin/CDK kinase assay
Recombinant cyclin/CDK holoenzymes are purified from Sf9 cells engineered to produce baculoviruses that express a specific cyclin or CDK. Cyclin/CDK complexes are typically diluted to a final concentration of 50 μg/mL in a kinase reaction buffer containing 50 mM Tris-HCl (pH 8.0), 10 mM MgCl2, 1 mM DTT, and 0.1 mM sodium orthovanadate. For each kinase reaction, 1 μg of enzyme and 20 μL of a 2-μM substrate solution (a biotinylated peptide derived from histone H1) are mixed and combined with 10 μL of diluted Dinaciclib. The reaction is started by the addition of 50 μL of 2 μM ATP and 0.1 μCi of 33P-ATP. Kinase reactions are incubated for 1 hour at room temperature and are stopped by the addition of 0.1% Triton X-100, 1 mM ATP, 5 mM EDTA, and 5 mg/mL streptavidin-coated SPA beads. SPA beads are captured using a 96-well GF/B filter plate and a Filtermate universal harvester. Beads are washed twice with 2 M NaCl and twice with 2 M NaCl containing 1% phosphoric acid. The signal is then assayed using a TopCount 96-well liquid scintillation counter.
Cell Research Cell lines A2780 cells
Concentrations 0 μM -5 μM
Incubation Time 24 hours
Method

A2780 cells are maintained in DMEM plus 10% fetal bovine serum and passaged twice weekly by detaching the monolayer with trypsin-EDTA. One hundred microliters of A2780 cells (5 × 103 cells) are added per well to a 96-well Cytostar-T plate and incubated for 16 hours to 24 hours at 37 °C. Dinaciclib is serially diluted in complete media plus 2% 14C-labeled dThd. Media are removed from the Cytostar T plate; 200 μL of various Dinaciclib dilutions are added in quadruplicate; and the cells are incubated for 24 hours at 37 °C. Accumulated incorporation of radiolabel is assayed using scintillation proximity and measured on a TopCounTM.

Experimental Result Images Methods Biomarkers Images PMID
Western blot Cleaved PARP / c-Myc Mcl-1 / Bcl-2 / Bcl-xl / Bax / Bak / PUMA / Noxa RNAP II (P-Ser2/P-Ser5) Survivin 25289887
Growth inhibition assay Cell viability Cell viability 28361959
Immunofluorescence cyclin B1 / α-tubulin / Aurora A OCT4 28207834
In Vivo
In vivo

Dinaciclib i.p. administration at 8, 16, 32, and 48 mg/kg daily for 10 days results in tumor inhibition by 70%, 70%, 89%, and 96%, respectively. Dinaciclib MED (minimum effective dose) appears to be <8 mg/kg. Dinaciclib is well tolerated, and the maximum body weight loss in the highest dosage group is 5%. Dinaciclib has dose-dependent antitumor activity in vivo, and that nearly complete inhibition of tumor growth occurs at a dose level below the MTD (maximum tolerated dose). Dinaciclib has a short plasma half-life in mouse. [1]

Animal Research Animal Models Nude mice bearing A2780 tumors
Dosages 8 mg/kg, 16 mg/kg, 32 mg/kg, and 48 mg/kg
Administration Administered via i.p.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03484520 Terminated
Cancer - Acute Myeloid Leukemia
AbbVie|Merck Sharp & Dohme LLC
July 23 2018 Phase 1
NCT01434316 Active not recruiting
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
November 1 2011 Phase 1

Chemical Information & Solubility

Molecular Weight 396.49 Formula

C21H28N6O2

CAS No. 779353-01-4 SDF Download Dinaciclib SDF
Smiles CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCCC4CCO
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 79 mg/mL ( (199.24 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 35 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
I want to know how to reconstitute the inhibitor for in vivo studies?

Answer:
S2768 (SCH727965) in 15% Captisol at 8 mg/ml is a suspension for oral administration. And it can be dissolved in 2% DMSO/30% PEG 300/ddH2O at 10 mg/ml as a clear solution for injection.

Tags: buy Dinaciclib | Dinaciclib supplier | purchase Dinaciclib | Dinaciclib cost | Dinaciclib manufacturer | order Dinaciclib | Dinaciclib distributor